Herke van Hulst

Advised the three former co-founders of Gorillas, Ronny Shibley, Jörg Kattner and Felix Chrobog, on the sale of their shares in Gorillas to Getir.

Advised the shareholders of MILabs on the sale of the company’s entire issued share capital to Rigaku Corporation, read more.

Advised DSM Venturing on the $47 million Series A funding round in innovative food company, Meatable. Read more >

Advised the syndicate of investors on VarmX’s EUR 32 million Series B financing round financing, read more.

Advised Oaky on $9.5M Series A financing by PeakSpan Capital, read more.

Advised on the sale of Isobionics to BASF, read more.

Advised the UK group Wildstone on the acquisition of the Spanish group of outdoor advertising Redext.

Advised Infosys on a strategic partnership with ABN AMRO, including the acquisition of a majority-stake in Stater.

Advised EQT Ventures on a co-lead €20m funding round for Amsterdam-based electric scooter company Dott

Advised a syndicate of investors led by Gilde Healthcare and Versant Ventures with additional support from US-based MRL Ventures Fund in the EUR 16 million financing round of Lava Therapeutics, read more

Represented the founders, INKEF Capital, Gilde Healthcare, Thuja Capital Healthcare, Health Innovation Fund, Van Herk Ventures (sellers) in the sale of NightBalance to Royal Philips. Nightbalance is a digital health scale-up company based in the Netherlands, that has developed an innovative, easy to use device to treat positional obstructive sleep apnea and positional snoring. Read more

Represented new investors INKEF Capital and Sectoral Asset Management as well as existing investors Sofinnova Ventures and Ysios Capital in respect of the USD 50 million Series B financing round of BioClin Therapeutics. Other investors include HealthCap, Tekla Capital Management funds and Life Sciences Partners (LSP). Read more

Advised EQT Ventures with the investment in Siilo, a secure mobile messaging service bringing medical teams together.

Advised HH Global, an award winning leading independent marketing execution partner to global brands in over 40 countries employing over 850 employees, with its acquisition of PostNL Print Management, the print management arm of the Dutch postal and logistic solutions provider PostNL, to help support HH Global’s growth in the Netherlands.

Represented Gilde Healthcare and key management (sellers) in the auction sale of ViroClinics Biosciences B.V. to Parcom Capital, a leading mid-market private equity firm in the Benelux, as well key management in their continuing investment in ViroClinics post-closing.

Advised A-Gas on the acquisition of Netherlands' reclamation business BTC.

Represented Terumo Corporation in respect of the staged transaction with Quirem Medical, in which Terumo Corporation following its initial minority interest (i)  increased its minority interest, (ii) acquired  the exclusive worldwide distribution rights and (iii) obtained a purchase option to acquire the remaining of the shares.

Represented Breath Therapeutics on EUR 43.5m Series A financing round by Gimv, Sofinnova Partners and Gilde Healthcare.

Represented Sofinnova Ventures and Ysios Capital as lead investors in the USD 30 million Series B Financing round of BioClin Therapeutics.

Advised lead investors Ysios Capital and Forbion Growth on Northsea Therapeutics' USD 80 million Series C financing round.

Osborne Clarke  has advised the shareholders of Genome Diagnostics B.V. (GenDx) in the competitive auction process relating to the sale of GenDx to Eurobio Scientific for an amount of €135 million.

Osborne Clarke assisted Mayht and its shareholders on the acquisition by Sonos and received the Best Deal Mid-Market award during the M&A Awards 2022.

Advised RS Group on the acquisition of Distrelec Group Holding B.V.